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Vasoactive intestinal peptide (VIP) is a potent anti-inflammatory neuropeptide that, by inhibiting Th1-
driven responses and inducing the emergence of regulatory T cells (Treg), has been proven successful in the
induction of tolerance in various experimental models of autoimmune disorders. Here, we investigate the
molecular mechanisms involved in VIP-induced tolerance. VIP treatment in the presence of T-cell receptor
(TCR) signaling and CD28 costimulation induced cell cycle arrest in human T cells. VIP blocked G1/S
transition and inhibited the synthesis of cyclins D3 and E and the activation of the cyclin-dependent kinases
(CDKs) cdk2 and cdk4. This effect was accompanied by maintenance of threshold levels of the CDK inhibitor
p27kip1 and impairment of phosphatidylinositol 3-kinase (PI3K)-Akt signaling. Inhibition of interleukin 2
(IL-2) transcription and downregulation of signaling through NFAT, AP-1, and Ras-Raf paralleled the VIP-
induced cell cycle arrest. Noteworthy from a functional point of view is the fact that VIP-treated T cells show
a regulatory phenotype characterized by high expression of CD25, cytotoxic-T-lymphocyte-associated protein
4 (CTLA4), and Forkhead box protein 3 (FoxP3) and potent suppressive activities against effector T cells.
CTLA4 appears to be critically involved in the generation and suppressive activities of VIP-induced Treg.
Finally, cyclic AMP (cAMP) and protein kinase A (PKA) activation seems to mediate the VIP-induced cell cycle
arrest and Treg generation.
Regulatory T cells (Treg) have emerged as a unique popu-
lation of suppressor T cells orchestrating peripheral immune
tolerance (54). Two major populations of Treg, with comple-
mentary and overlapping functions in the control of immune
response in vivo, have been characterized: naturally occurring,
thymus-generated CD4 CD25 Forkhead box protein 3
(FoxP3)-expressing Treg and peripherally induced Treg (38, 54).
Numerous studies have demonstrated the successful therapeu-
tic use of antigen-specific Treg in various experimental models
of autoimmune diseases and allogeneic transplantation, pro-
viding long-term tolerance by active and specific regulation of
self-antigen- and alloantigen-specific T cells (7, 38). However,
the translation of important biological findings about Treg-
based immunotherapy to the clinic has been limited mainly by
the inability to define their antigenic specificities and by the
scarcity of circulating Treg. To solve this problem, two different
strategies have been proposed, either facilitating in vivo Treg
function or infusing Treg isolated and manipulated/expanded
ex vivo. Several approaches have been used to expand naturally
occurring human CD4 CD25 Treg, mainly by T-cell receptor
(TCR)-CD28 stimulation in combination with interleukin 2
(IL-2) and/or IL-15 (36, 47). An alternative approach consists
of the conversion of CD4 CD25 Treg from conventional
CD4 T cells with inducible factors. Whereas a large body of
literature has been dedicated to describing how Treg control
ongoing immune responses and tolerance, especially regarding
their phenotype, ontogeny, and mechanisms of suppression
(38, 54), the endogenous molecules controlling the peripheral
expansion or de novo generation of Treg remain largely un-
known. For example, the suppressive cytokine transforming
growth factor 1 (TGF-1) or immunosuppressive drugs, such
as FK778, generate CD4 CD25 Treg from the CD4
 CD25
T-cell compartment (14, 19, 35, 53, 66, 67). The identification
of additional Treg-inducing factors should extend the applica-
bility of immunotherapy based on Treg in human patients.
Vasoactive intestinal peptide (VIP) is an immunosuppres-
sive neuropeptide with potent anti-inflammatory effects (16).
VIP is produced by Th2 cells upon antigenic stimulation and
mediates regulatory actions on both innate and adaptive im-
munity (16). Indeed, VIP-based therapy has been proven suc-
cessful in the treatment of various experimental models of
inflammatory and autoimmune disorders (25). Beside its in-
hibitory effect on inflammatory and Th1-driven responses, VIP
induces the emergence of Treg in animals with experimental
autoimmune encephalomyelitis and arthritis (20, 26). The in
vivo VIP-induced Treg seem to consist of two populations: a
major population of FoxP3 CD4 CD25 Treg, the suppres-
sive mechanism for which is mediated through direct cellular
contact that is mainly dependent on cytotoxic-T-lymphocyte-
associated protein 4 (CTLA4), and a minor CD4 T-cell pop-
ulation, which uses IL-10 and/or TGF-1 as a suppressive
molecule (29). We have recently reported the potential of VIP
to promote immune tolerance for alloantigens by generating
Treg displaying suppressive functions against allospecific effec-
tor T cells and protecting against acute graft-versus-host dis-
ease in a mouse model of allogeneic bone marrow transplan-
tation (48). The aim of this study was to investigate the
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molecular mechanisms involved in the immunosuppressive
activity of VIP on human T cells and on the generation of
human Treg.
MATERIALS AND METHODS
Antibodies and reagents. VIP, secretin, pituitary adenylate cyclase (AC)-
activating polypeptide (PACAP), VIP10-28, VIP1-12, okadaic acid, forskolin,
8-Br-cyclic AMP (cAMP), H-89 {N-[2-(p-bromocinnamylamino)ethyl]-5-iso-
quinolinesulfonamide}, histone H1, and anti-laminin B monoclonal antibody
(MAb) were from Calbiochem. Rp-cAMP was from Boehringer Mannheim
GmbH. Antibodies (Abs) against phospho-AktSer473, phosphoinositide-de-
pendent protein kinase 1 (PDK-1), Akt, ERK1/2, MEK1, phospho-MEK1,
phospho-lckTyr394, FoxO1, and phospho-FoxO1Ser256, as well as glutathione-
S-transferase (GST)–retinoblastoma protein (Rb)-(769–921) fusion protein,
were from Cell Signaling Technology. Fluorescein isothiocyanate (FITC)-
conjugated anti-CTLA4, phycoerythrin (PE)-conjugated anti-CD25, Alexa-con-
jugated anti-phospho-STAT5, peridinin chlorophyll protein (PerCP)-conjugated
anti-CD4, anti-pRb, anti-CD3, and anti-IL-10 were from BD PharMingen. Anti-
phospho-Raf1Ser259 and anti-phospho-Raf1Ser43 Abs were from New England
Biolabs and Millipore, respectively. Protein A/G agarose and antibodies against
CD3 chain, cyclin E, cyclin A, cdk2, cyclin D2, cyclin D3, cdk4, cdk6, Rap1,
p27kip1, phospho-ERK1/2, p38, phospho-p38, c-Jun, and phospho-c-Jun were
from Santa Cruz Biotechnology. Phytohemagglutinin (PHA), enolase, and anti-
-tubulin Ab were from Sigma. Staphylococcal enterotoxin B (SEB) was from
Toxin Technology. Anti-p27kip1 and anti-NFATp MAbs were from BD Trans-
duction Laboratories. Anti-Raf1 Ab was from Transduction Laboratories, and
anti-Ras Ab was from Oncogene. Human granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) and IL-4 were from R&D Systems and human IL-2
from Roche Biomedical. FITC- and Alexa-conjugated anti-human FoxP3 (clones
PCH101 and 236A/E/) and anti-human programmed-death 1 (anti-PD-1) Abs
were from eBioscience. The phosphatidylinositol 3-kinase (PI3K) activator 740
Y-P was obtained from Tocris Bioscience. Peroxovanadate was prepared fresh by
incubating sodium vanadate and H2O2 (12 mM each) at 20°C in 40 mM HEPES
(pH 7.4) for 15 min.
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coat preparations from healthy volunteers by density sedimentation
on Ficoll-Hypaque gradients (20 min; 700  g; 20°C). Cells recovered from the
gradient interface were washed twice in RPMI 1640 medium and immediately
used for culture or further purification. To isolate T cells, PBMCs were depleted
of adherent cells by incubation in plastic dishes and then with anti-CD8, -CD14,
-CD19, -CD20, and -CD56 MAbs (Coulter Immunotech) for 1 h at 4°C, followed
by incubation with anti-mouse IgG-coated magnetic beads (45 min; 4°C). Bead-
bound cells were removed from the PBMCs with a magnetic device. To minimize
stimulation of the cells, all the purification steps were carried out in the absence
of serum. The purity of the T cells was 96% as assessed by flow cytometry.
CD4 T cells were isolated by negative selection from the total PBMCs using a
CD4 isolation kit (Miltenyi Biotec), yielding a population of CD4 cells with
purities of 94 to 98%. Positive selection on anti-CD25 magnetic microbeads was
then used to separate the negative fraction containing CD4 CD25 T cells from
the CD4 CD25 T-cell fraction, using the CD4 CD25 T Regulatory Cell
Isolation kit (Miltenyi Biotec). This procedure led to the complete positive
selection of CD4 CD25 T cells (purity, 96%) and negative depletion of
CD4 CD25 T cells, as measured by flow cytometry. In some experiments, the
different T-cell populations (CD4, CD4 CD25, and CD4 CD25) were
isolated by sorting using a FACS-Calibur flow cytometer (Becton Dickinson)
after the cells were labeled with PE–anti-CD25 and PerCP–anti-CD4 Abs as
described below.
To generate human dendritic cells (DCs), monocytes (2  106) were isolated
from the PBMC fraction by adherence to plastic and cultured in RPMI 1640
medium containing GM-CSF (800 U/ml) and IL-4 (500 U/ml). After 6 days,
nonadherent cells were collected and negatively selected with anti-CD2 and
anti-CD19 MAb-coated beads. The resultant cells were cultured for 48 h with
lipopolysaccharide (LPS) (1 g/ml) to induce activation/maturation.
Cell cultures and stimulation. Purified human T cells or CD4 cells (106/ml)
were cultured in complete medium consisting of RPMI 1640 medium supple-
mented with human AB serum (8%), L-glutamine (200 mM), sodium pyruvate
(1%), nonessential amino acids (1%), penicillin-streptomycin (1%), and 2-mer-
captoethanol (1%) at 37°C and 5% CO2. The cells were stimulated with anti-
CD3/anti-CD28 MAb-coated magnetic beads (Invitrogen; one bead per cell),
PHA (1 g/ml), or the superantigen SEB (1 ng/ml) for different times. VIP was
added at different concentrations with the different stimuli. In some experiments,
VIP was added at different times after cell stimulation or at the same time as
CD3/CD28 stimulation and removed by extensive cell washing at various times
after initiation of culture. The proliferative response was determined by incu-
bating human T cells (105/well) or CD4 CD25 T cells (2.5  105/well) in
complete medium in 96-well flat-bottom plates (Costar) with the indicated fac-
tors, pulsing them with 0.5 Ci (0.0185 MBq)/well [3H]thymidine for the last 8 h
of the culture, and harvesting them onto membranes; the incorporated [3H]thy-
midine was measured in a liquid scintillation counter.
In some experiments, cells were harvested after 4 days of primary stimulation,
washed, and rested for 2 days. The viable cells (5  104) were recovered by
centrifugation in density gradient (Lymphoprep; Nycomed Pharma AS) and
restimulated in a secondary culture with HLA-mismatched DCs (104), IL-2 (20
to 50 U/ml), anti-CD3 (2 g/ml), and/or anti-CTLA4 antibody (10 g/ml). When
indicated, PBMCs (2  106) were activated with tetanus toxoid (TT) (1 g/ml)
in the absence or presence of VIP. After 4 to 6 days, T cells (2  104) were
isolated from the primary culture as described above, rested for 2 days, and
restimulated on a secondary culture with mature DCs (104) from the same donor
in the absence or presence of TT (1 g/ml).
T-cell suppression assays. The suppressive capacity of VIP-treated cells was
analyzed in a coculture assay. Human T cells or CD4 CD25 T cells isolated
from donor A were activated with anti-CD3/CD28 MAb-coated beads with or
without 107 M VIP. After 4 days, cells were harvested, rested for 2 days, and
added at different ratios to cocultures of responder T cells (5  104, from donor
A) and allogeneic mDCs (104, from donor B). Some cultures were performed in
the presence of blocking anti-IL-10 or anti-CTLA4 (10 g/ml) Abs or of IL-2
(100 U/ml). In similar experiments, responder CD4 T cells (from donor A)
were labeled with 2.5 M carboxyfluorescein diacetate succinimidyl ester
(CFSE) (Molecular Probes) prior to setting up cocultures, and proliferating cells
were determined by CFSE dilution by fluorescence-activated cell sorting
(FACS). To determine the cell contact dependence of the suppressive response,
we placed responder T cells (5  104) with allogeneic mDCs (104) in the bottom
well of a Transwell system (Millipore; 0.4-m pore) and the recovered T cells
(2  104) with allogeneic mDCs (104) in the upper Transwell insert. At day 4, the
proliferation of the responder cells in the lower compartment was determined.
Cell cycle analysis. Cells (106) were fixed in ice-cold 70% ethanol for 1 h,
washed, incubated with 0.1% RNase–phosphate-buffered saline (PBS) (37°C; 45
min), and stained with 50 g/ml propidium iodide (37°C; 30 min) prior to FACS
analysis for DNA content using CellQuest software. Viability was determined by
flow cytometry using an annexin V-based apoptosis detection kit (R&D
Systems). Moreover, cell numbers were determined by counting cells exclud-
ing trypan blue after 72 h of culture.
Western blot analysis and in vitro kinase assays. Proteins from whole-cell,
nuclear, and cytoplasmic extracts were prepared as described previously (15),
separated (70 g/lane) by SDS-polyacrylamide gel electrophoresis (PAGE)
(12%; 8% for phosphorylated Rb [pRb]), and blotted onto polyvinylidene diflu-
oride membranes (Millipore) using a semidry system. The membranes were
blocked (Tris-buffered saline–Tween 20–3% nonfat dry milk; 1 h; 22°C), probed
with the indicated primary antibody overnight at 4°C, immunodetected with
horseradish peroxidase-conjugated secondary antibodies, and visualized by en-
hanced chemiluminescence (ECL) (Amersham Pharmacia). Equal protein load-
ing was controlled by reprobing with anti-actin, anti-Zap70 (zeta chain-associ-
ated protein kinase), anti--tubulin, or anti-laminin B antibody. The band
intensity was quantitatively determined with ImageJ software (National Insti-
tutes of Health) and expressed as densitometric units normalized for the expres-
sion of actin, Zap70, -tubulin, or laminin B in each sample. The levels of
phosphorylated proteins were normalized to the total expression of the corre-
sponding protein.
To study the association between cyclin/cyclin-dependent kinase (CDK) com-
plexes and p27kip1, endogenous cdk4, cdk2, cyclin D2, cyclin E, and cyclin D3
were immunoprecipitated from whole-cell lysates (250 g/sample) by incubation
with the corresponding antibody (5 g; 2 h; 4°C), followed by incubation with
protein A/G-Sepharose beads (10 g; 45 min; 4°C) under constant agitation. The
beads were extensively washed with lysis buffer and subjected to immunoblot
analysis of cyclins, CDKs, and p27kip1 as described above.
To assay cyclin- and CDK-associated kinase activities, whole-protein extracts
(500 g) were immunoprecipitated with anti-cdk2, anti-cyclin E, anti-cdk4, anti-
cyclin D3, and anti-cyclin D2 antibodies as described above. After extensive
washing, the kinase activities in the immunoprecipitates were assayed (30 min;
30°C) in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 2.5 mM EGTA, 1 mM
dithiothreitol, 10 mM -glycerophosphate, 0.1 mM Na3VO4, 1 mM NaF, 50 M
cold ATP, 10 Ci of [-32P]ATP (6,000 Ci/mmol), and 5 g of histone H1 for
cdk2 and cyclin E or 2 g of Rb-GST for cdk4 and cyclin D2/D3. The phosphor-
ylated proteins were separated by SDS-PAGE, transferred to Immobilon P
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membranes (Millipore), and analyzed by Western blotting. The optical densities
of the bands were determined as described above and expressed as densitometric
units relative to values obtained on unstimulated controls.
Phosphorylated p27kip1 was determined by immunoprecipitation of cell lysates
with anti-p27kip1, followed by immunoblotting with anti-phospho-Thr antibody.
Akt/protein kinase B (PKB) activity in whole lysates was measured using an Akt
Kinase Assay kit (Cell Signaling) by immunoprecipitation of cell lysates with an
anti-Akt MAb, followed by immunocomplex kinase assay in the presence of
GSK-3 fusion protein as a substrate. The Raf1 kinase assay was performed by
measuring the phosphotransferase activity toward GST-MEK1 (50). Determina-
tion of the active form of CD3 was conducted, as previously described (58), by
determining the levels of phospho-Tyr by immunoblotting of immunoprecipitates
for the  chain. Fyn activity was determined by immunoprecipitation with anti-
Fyn Abs and measuring the phosphotransferase activity toward enolase using a
previously described in vitro kinase assay (56). PKA activity was determined by
using the PKA assay kit from Upstate Biotechnology, which measures the phos-
photransferase activity toward kemptide (used as a specific substrate). cAMP
levels in the lysates were determined by the nonacetylation method using an
enzyme immunoassay system (Amersham Pharmacia Biotech).
The activation of Ras and Rap1 was studied by detecting the GTP-bound
forms of Ras and Rap1, respectively. Ras-GTP and Rap1-GTP were affinity
purified from cell lysates by the use of GST-Raf1-RBD and GST-RalGDS-RBD,
respectively, coupled with glutathione-Sepharose beads (30). Complexes were
analyzed by 15% SDS-PAGE and immunoblotting with anti-Ras and anti-Rap1
antibodies.
EMSA. The electromobility shift assay (EMSA) was performed with nuclear
extracts using STAT5, AP-1, NF-	B, or NFAT consensus oligonucleotides as
described previously (34, 52).
Flow cytometry. Cells were incubated with various PerCP/Alexa/FITC/PE-
labeled antibodies diluted at the optimal concentration for immunostaining,
fixed in 1% paraformaldehyde, and analyzed on a FACScalibur cytometer.
We used isotype-matched antibodies as controls. For analysis of intracellular
CTLA4, FoxP3, and phosphorylated STAT5, cells were first stained for surface
CD4 and CD25; fixed with Cytofix/Cytoperm solution (BD PharMingen); incu-
bated with FITC–anti-CTLA4, FITC–Alexa–anti-FoxP3, or Alexa–anti-phos-
pho-STAT5 antibody diluted in 0.5% saponin; and analyzed by FACS.
Intracellular calcium fluxes were determined by flow cytometry using Indo-1 (2
M; Molecular Probes) as previously described (58).
Cytokine determination. The cytokine contents of the culture supernatants
were determined by specific sandwich enzyme-linked immunosorbent assays
(ELISAs) using capture/biotinylated detection Abs from BD Pharmingen. For
intracellular-cytokine analysis, viable T cells (106/ml) recovered by gradient cen-
trifugation after stimulation were cultured with phorbol myristate acetate (PMA)
(10 ng/ml) plus ionomycin (50 ng/ml) for 6 h. Monensin (1.33 M) was added for
the last 4 h of culture. Cells were stained with PerCP–anti-CD4 MAbs for 30 min
at 4°C, fixed/saponin permeabilized with Cytofix/Cytoperm, and stained with
FITC-conjugated anti-IL-2, anti-gamma interferon (anti-IFN-), anti-IL-4, anti-
tumor necrosis factor alpha (anti-TNF-
), or anti-IL-10 MAb (0.5 g/sample; 45
min;4°C; BD Pharmingen), and analyzed by flow cytometry.
Cell transfection and luciferase assay. Jurkat T cells were transiently trans-
fected with 20-g reporter constructs of luciferase driven by the 2-kb IL-2
promoter/enhancer, AP-1, NFAT, or NF-	B (Clontech and Stratagene) as de-
scribed previously (30). After 48 h of transfection, 5  105 cells were cultured for
6 h as indicated in each experiment, and luciferase activity was measured. The
transfection efficiency was normalized by cotransfection with pEF-lacZ and assay
for -galactosidase.
mRNA expression. CTLA4 gene expression was determined by reverse tran-
scription (RT)-PCR as previously described (60). mRNA expression of p27kip1
was determined by Northern blot analysis according to standard methods (15),
using a probe for human p27kip1 synthesized by RT-PCR with the primers
5-GCAACCGACGATTCTTCTAC-3 and 5-GTCCATTCCATGAAGTCAG
C-3 under the following PCR conditions: denaturation at 94°C for 5 min,
followed by 25 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s. FoxP3 gene
expression was quantitated by real-time PCR as previously described (57).
mRNA expression of B- and T-lymphocyte attenuator (BTLA) was determined
by Northern blot analysis using a probe for human BTLA cDNA synthesized as
described previously (62).
Data analysis. All values are expressed as mean  standard deviation (SD).
Statistical comparisons between experimental groups were done with Duncan’s
multiple-range test after two-way analysis of variance (ANOVA). P values
of 0.05 were considered significant.
RESULTS
VIP induces cell cycle arrest in human activated T cells. We
first established the immunosuppressive effects of VIP on hu-
man T cells in vitro by assessing the inhibitory potential of VIP
for the proliferation of T cells stimulated by different stimuli,
including mitogen PHA, superantigen SEB, or anti-CD3/
CD28-coated beads (see Fig. S1A in the supplemental mate-
rial). Because signaling through TCR/CD3 and CD28 costimu-
lation represents the most physiological condition of antigenic
activation of T-cell effector functions, we selected this stimu-
lation (referred to here as CD3/CD28) for further experiments.
VIP decreased, in a dose-dependent manner, the clonal expan-
sion and cytokine production of CD3/CD28-activated primary
human T cells (Fig. 1). Cell cycle analysis showed that VIP
strongly reduced the number of T cells in S phase and pre-
vented the decrease of cells in G0/G1 observed after CD3/
CD28 stimulation (Fig. 1). This suggests that VIP prevented
exit from G0/G1 and entry into S phase of the cell cycle of
activated T cells. The suppressive action of VIP was not due to
an effect on survival or apoptosis (Table 1). An initial delay of
2 to 6 h in the addition of VIP after CD3/CD28 stimulation did
not alter its effect on cell cycle progression; however, a delay of
12 h reduced its inhibitory effect (Table 2). The converse ex-
periments indicated that a brief treatment (2 h) with VIP
after CD3/CD28 stimulation was sufficient to inhibit exit from
G0/G1 (Table 2). These findings indicate that the antiprolif-
erative signal of VIP is fully delivered very early and within a
narrow window of time after stimulation, although it is main-
tained long term.
We next investigated the specificity of the effects of VIP. The
immunological actions of VIP are exerted through a family of
receptors consisting of VPAC1 and VPAC2 (29). VIP actions on
the T-cell cycle and proliferation were reversed by a selective
VPAC1 antagonist (Table 1). Moreover, PACAP, a VIP-related
neuropeptide that also binds to VPAC1, mimicked the effects of
VIP; however, the VIP fragments VIP1-12 and VIP10-28, as well as
FIG. 1. VIP induces cell cycle arrest in human T cells. Primary
human T cells were cultured with medium alone (unstimulated; gray
bars) or activated with anti-CD3/CD28 MAb-coated beads (CD3/
CD28) in the absence or presence of different concentrations of VIP.
Cytokine levels in culture supernatants were determined after 48 h by
ELISA. Cell numbers were determined by counting cells excluding
trypan blue at 72 h. Proliferation was determined by [3H]thymidine
incorporation at 96 h. The percentages of cells in G0/G1 and S phases
were determined by flow cytometry at different time points. *, P  0.01
versus CD3/CD28 (n  4, in duplicate). The error bars indicate SD.
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secretin and glucagon (two peptides of the VIP family), failed
to efficiently induce T-cell cycle arrest (Table 1).
VIP generates T cells with suppressive functions. We next
investigated the capacity of the VIP-treated T cells to respond
to different stimuli in a secondary culture in the absence of the
neuropeptide. Whereas restimulation of CD3/CD28-activated
T cells with anti-CD3 Abs or with allogeneic mDCs resulted in
the induction of functional effector T cells characterized by a
fast proliferative response, the cells that were primed in the
presence of VIP did not proliferate in response to secondary
stimulation to alloantigens (Fig. 2A; see Fig. S1B in the
supplemental material) or to a specific antigen (Fig. 2B).
This hyporesponsive state was partially reversed by the ad-
dition of IL-2, but not blockade of the immunosuppressive
molecule CTLA4 (Fig. 2A). Moreover, CD3/CD28-primed
T cells showed increased production of the effector cytokines
IL-2, IL-4, IFN-, and TNF-
 upon restimulation, whereas
VIP treatment substantially reduced the number of CD4 cells
producing all these cytokines (Fig. 2C). In contrast, VIP in-
creased the number of cells producing the suppressive mole-
cules IL-10 and TGF-, mainly in the nondividing subset, in-
dicating that this effect is not a result of the expansion of
preexisting IL-10/TGF--producing cells (Fig. 2C). Whether
VIP induces the generation of these cells from naïve T cells or
converts Th1 or Th2 cells to IL-10/TGF--producing cells is
still unknown, but VIP did not increase the expression of IL-10
or TGF- on human Th1 and Th2 clones (unpublished data).
The VIP-induced hyporesponsiveness seems to be antigen spe-
cific, because T cells from donor 1 primed with allogeneic
antigen-presenting cells (APCs) from donor 2 in the presence
of VIP did not respond to a secondary restimulation with APCs
from donor 2 but did with respond to a secondary restimula-
tion with APCs from donor 3 (Fig. 2D).
Various reports have closely related T-cell cycle arrest to a
regulatory phenotype (10, 11, 37). Moreover, it has been shown
that treatment with VIP of mice with autoimmune disorders
increases the number of Treg in the periphery (20, 26, 28).
Therefore, we investigated whether the human T cells primed
in the presence of VIP exerted suppressor activity on effector
T cells. To address this issue, human T cells activated with
CD3/CD28 in the absence (Tcontrol) or presence (TVIP) of VIP
were cocultured at different ratios with syngeneic T cells and
allogeneic mDCs. Whereas Tcontrol significantly contributed to
the proliferative response of effector T cells, TVIP dose-depen-
dently suppressed their clonal expansion (Fig. 3A). Separation
of TVIP from responder T cells in transwells significantly re-
versed the suppressive effect of TVIP, and blocking of CTLA4,
but not of IL-10, fully reversed it (Fig. 3B), suggesting a
CTLA4 cell-to-cell dependence. As expected, IL-2 addition to
cocultures bypassed their suppressive activity (Fig. 3B). The
involvement of CTLA4 in the suppressive effect of TVIP cor-
related with the fact that VIP induced rapid and sustained
expression of both soluble and membrane-bound forms of
CTLA4 in CD3/CD28-activated T cells (Fig. 3C; see Fig. S2 in
the supplemental material). In contrast to its effect on CTLA4,
VIP failed to increase the expression of other molecules in-
volved in inhibitory signals on T cells, including PD-1 and
BTLA (see Fig. S2 in the supplemental material), and block-
ade of PD-1-mediated signaling with anti-PDL1 Abs did not
affect the suppressive activity of TVIP on effector T cells (not
shown).
Similar regulatory activities were obtained when we used
purified CD4 CD25 T cells primed in the presence of VIP
TABLE 1. Effects of agonists, antagonists and fragments of VIP on activated T cells
Stimulationa Proliferationb IFN- (ng/ml)c % G0/G1d % S phased % Apoptosise
Unstimulated 7.6  1.1 0.4  0.1 90  3 4  2 5  0.8
CD3/CD28 42.3  5.2 4.7  0.4 54  4 34  4 11  0.8
 VIP 18.3  2.1f 1.1  0.3f 79  3f 14  3f 10  1.7
 PACAP 19.5  1.9f 1.2  0.4f 77  4f 16  3f 11  1.5
 Gastrin 39.7  5.2 4.6  0.9 58  3 32  3 12  2.3
 Glucagon 43.5  3.6 4.8  0.4 53  4 35  2 10  0.9
 VIP1-12 41.9  3.2 4.5  0.8 55  5 35  4 12  2.2
 VIP10-28 43.5  3.1 4.9  0.5 53  3 36  3 12  1.7
 VIP  VPAC1 antagonist 38.4  4.2g 4.1  0.6g 60  5g 30  4g 11  2.1
a Primary human T cells were incubated with medium alone (unstimulated) or activated with anti-CD3/CD28 beads in the presence of VIP (107 M), PACAP (107 M),
glucagon (107 M), gastrin (107 M), VIP1-12 (107 M), or VIP10-28 (107 M) or of VIP (107 M) plus VPAC1 antagonist (106 M).
b Proliferation was determined by 3Hthymidine incorporation at 96 h and expressed as 103 cpm.
c IFN- levels were determined by ELISA in supernatants collected at 48 h.
d Percentages of cells in G0/G1 and S phases were determined by FACS at 72 h.
e Apoptotic cells were determined at 48 h by FACS after propidium iodide and annexin V staining.
f P  0.01 versus CD3/CD28 (n  4, in duplicate).
g P  0.05 versus VIP-treated samples (n  4, in duplicate).
TABLE 2. Window for VIP effects on cell cycle arrest of
human T cells
Treatmenta Cells in G0/G1(% of total)b
Cells in S phase
(% of total)b
CD3/CD28 only 55  3 32  3
CD3/CD28  VIP added at t  0 78  2c 14  2c
VIP added 2 h after CD3/CD28 76  2c 15  3c
VIP added 6 h after CD3/CD28 72  3c 17  2c
VIP added 12 h after CD3/CD28 67  4d 24  4d
VIP removed 2 h after CD3/CD28 77  3c 18  3c
VIP removed 6 h after CD3/CD28 76  4c 16  2c
VIP removed 12 h after
CD3/CD28
77  2c 17  3c
a Primary human T cells were activated with anti-CD3/CD28 beads (CD3/
CD28 only). VIP (107 M) was added to cultures at different times after acti-
vation. Alternatively, VIP was added with CD3/CD28 stimulation and removed
at different times after the initiation of culture by extensive washing.
b Percentages of cells in G0/G1 and S phases were determined by FACS at 72 h.
c P  0.01 versus CD3/CD28 only (n  4 or 5, in duplicate).
d P  0.05 versus CD3/CD28 only (n  4 or 5, in duplicate).
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(see Fig. S3 in the supplemental material). These data suggest
that the induction of regulatory activity by VIP occurs within
the CD4 CD25 T-cell fraction, independent of the pres-
ence and expansion of naturally occurring CD4 CD25
Treg. FACS analysis indicated that three distinct subsets
were distinguished based on the level of CD25 expression
(CD25negative, CD25intermediate, and CD25high) after VIP treat-
ment (Fig. 3D). We sorted the three populations and examined
FoxP3 and CTLA4 expression as Treg markers, and their func-
tional activities. An elevated percentage of the VIP-induced
CD25high population expressed FoxP3 and CTLA4high in com-
parison to the CD25high cells purified from the untreated con-
trols (Fig. 3D). This was due to an increase in the absolute
number of CD4 FoxP3 and CD4 CTLA4 T-cell subsets,
but not to enrichment of these cells due to a decrease in the
number of effector cells (not shown). The VIP-induced
FIG. 2. VIP induces hyporesponsiveness in T cells. (A) Human T cells were CD3/CD28 activated in the absence or presence of VIP (107M)
for 96 h. Cells were harvested and rested for 48 h, and the recovered viable cells were restimulated in a secondary culture with allogeneic mDCs
in the absence or presence of IL-2 or anti-CTLA4 MAb. Proliferation was determined at different times after initiation of secondary culture.
*, P  0.01 versus CD3/CD28 (n  4, in duplicate). The error bars indicate SD. (B) Human PBMCs (10
7) were activated with TT in the absence
or presence of VIP (107 M) for 4 days, and proliferation in this primary culture was determined by [3H]thymidine incorporation (top). T cells
(2  104) were isolated from the primary culture, rested for 2 days, and restimulated in a secondary culture with syngeneic mDCs (104) in the
absence or presence of TT, and proliferation was determined after 4 days (bottom). *, P  0.01 versus TT-primed cells in the absence of VIP (n 
3, in duplicate). (C) CFSE-labeled human T cells were CD3/CD28 activated in the absence or presence of VIP (107 M) for 96 h. Cells were
harvested and rested for 48 h, and the cytokine-producing potential of the recovered cells was determined by intracellular cytokine staining on
CFSEhigh (nondividing; R1) and CFSEmild/low (cycling; R2) cells using flow cytometry. The numbers represent the percentages of cytokine-positive
cells (n  4). unstimul., unstimulated. (D) T cells from donor 1 (5  104) were labeled with CFSE and stimulated with mDCs from donor 2 (APC2;
2  104) in the absence or presence of VIP. After 6 days, viable cells (2  104) were recovered and restimulated in a secondary culture with medium
(None), with APC2 (104), or with mDCs from donor 3 (APC3; 104). The number of CFSElow/mild cycling cells was determined after 4 days of
secondary culture. *, P  0.01 (n  3 or 4, in duplicate).
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CD25high subset elicited weak proliferation, did not express
markers of activation (they are CD69 CD62Lhigh), and re-
mained hyporesponsive upon allogeneic restimulation with
mDCs (see Fig. S4 in the supplemental material). Moreover,
the expression of FoxP3 on these cells was confined to the
noncycling cells (see Fig. S4A in the supplemental material),
supporting the idea that VIP would induce the generation of
new Treg rather than a mere enrichment of existing cells.
The addition of VIP-induced CD25high cells to cocultures of
PBMCs and allogeneic mDCs impaired the proliferation of
responder T cells (Fig. 3E). However, the VIP-induced
CD25intermediate population showed weak suppressive activ-
ity (Fig. 3E) while showing increased expression of CTLA4
and moderate FoxP3 (Fig. 3D). Taken together, these results
indicate that stimulation via TCR/CD3-CD28 signaling in the
presence of VIP resulted in de novo generation of a CD4
CD25high CTLA4 T-cell population with regulatory func-
tions.
Although the contribution of TGF- to the suppressive ac-
tivity of induced Treg is controversial, its critical participation
in their generation is clearly established (14, 19, 53, 57, 66).
Moreover, a previous study demonstrated that TGF-1 re-
quires CTLA4 to induce FoxP3 expression and to generate
Treg functions (67). By using neutralizing antibodies, we dem-
onstrated that CTLA4 is needed for VIP to induce FoxP3 in
CD3/CD28-activated CD4 CD25 T cells (Fig. 4A) and to
generate suppressor T cells (Fig. 4B). However, TGF- did not
participate in any of these VIP effects (Fig. 4A and B).
VIP-induced suppressive T cells are arrested at the G1
phase of the cell cycle. The results described above suggest that
VIP must regulate the signals controlling cell cycle progres-
sion. Unraveling such signals is critical to understanding how
VIP induces T cells with regulatory functions. TCR/CD3 plus
CD28 costimulation regulates the entry of T cells into the cell
cycle and progression through the G1 phase, leading to down-
regulation of the CDK inhibitor p27kip1 and activation of cyclin
D2-associated cdk4/cdk6 and cyclin E-associated cdk2. These
events result in hyperphosphorylation of the retinoblastoma
(pRb) gene product, expression of S-phase genes, and cell
cycle progression (4, 63). Analysis of the cell cycle regulatory
FIG. 3. VIP induces regulatory functions in human T cells. (A) Human T cells isolated from donor A were CD3/CD28 activated in the absence
(Tcontrol) or presence (TVIP) of VIP for 4 days. After a 48-h rest period, the suppressive potential of the recovered cells (suppressor Tcontrol or TVIP)
was determined by adding increasing numbers of Tcontrol or TVIP to cocultures of responder T cells (from donor A) and allogeneic mDCs (from
donor B). The proliferation of responder T cells was determined after 4 days. The black bar represents background proliferation of unstimulated
responder T cells. The error bars indicate SD. (B) Tcontrol or TVIP (2.5  10
4) were added to cocultures of responder T cells (donor A; 5  104)
and allogeneic mDCs (donor B) in the absence or presence of IL-2 (100 U/ml), anti-CTLA4 (10 g/ml), or anti-IL-10 (10 g/ml) MAb. When
indicated, TVIP-mDC cocultures were separated from responder T-cell–mDC cocultures by a semipermeable membrane in transwells. The
proliferation of responder T cells was determined after 4 days. The dashed line represents background proliferation of unstimulated responder T
cells. (C) The human T cells isolated were CD3/CD28 activated in the absence or presence of VIP for different times. The mRNA expression of
the soluble and membrane (memb) forms of CTLA4 was determined by quantitative PCR and expressed as arbitrary units normalized by -actin
transcripts. The time course corresponds to total mRNA (soluble plus membrane CTLA4). (D) CD4 CD25 T cells isolated from donor A were
CD3/CD28 activated without (Tcontrol) or with (TVIP) VIP for 96 h. Tcontrol and TVIP were analyzed in the CD4
 cell fraction for CD25 expression
by flow cytometry. The subsets formed (CD25negative, CD25intermediate, and CD25high) were sorted by flow cytometry and analyzed for FoxP3 and
CTLA4 expression. (E) Sorted CD25negative, CD25intermediate, and CD25high populations from Tcontrol and TVIP were added at different cell ratios
to cocultures of PBMCs (5  104) and allogeneic mDCs, and proliferation was determined. n  3 or 4, in duplicate, for all panels, except panel
C, where n  2. *, P  0.01 versus Tcontrol; #, P  0.01 versus TVIP-treated cocultures.
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molecules showed that VIP-treated T cells were capable of
expressing cyclin D2 and cyclin-associated cdk4 and cdk6, in-
dicating that they could enter the G1 phase (Fig. 5A; see Fig.
S5 in the supplemental material). However, VIP blocked pro-
gression through the G1 restriction point to the late G1 and S
phases. VIP-treated cells showed sustained decrease in the
expression of cyclin D3, which is synthesized in the late G1
phase, and cyclin E, which is expressed at the G1 restriction
point. Consequently, the levels of S-phase cyclin A were dra-
matically reduced by VIP (Fig. 5A; see Fig. S5A in the sup-
plemental material). Moreover, whereas T-cell activation via
CD3/CD28 downregulated p27kip1 levels, VIP treatment not
only avoided the degradation of this CDK inhibitor, but also
increased its levels over the background expression found in
unstimulated cells. As a result of these events, hyperphosphor-
ylation of pRb was impaired in VIP-treated cells (Fig. 5A; see
Fig. S5A in the supplemental material). It is noteworthy that
exogenous IL-2 partially, but not totally, reversed the VIP
effects on the expression of cyclin E, cyclin A, or p27kip1 (Fig.
5B; see Fig. S5B in the supplemental material), consistent with
the hypothesis that IL-2 inhibition by VIP could contribute to
cell cycle arrest. In contrast, IL-2 addition to untreated CD3/
CD28-activated T cells did not affect the expression of cyclins
or p27kip1, suggesting that the IL-2 endogenously produced
with T-cell activation is sufficient to induce these molecular
events.
The effect of VIP in cell cycle progression was accompanied
by impaired activation of both cyclin D2/D3-associated cdk4
and cyclin E-associated cdk2 kinase activities (Fig. 5C; see Fig.
S5C in the supplemental material). This confirms and extends
the observation that VIP affects the functions of the molecular
players involved in the G1/S progression.
VIP elevates the levels of p27kip1 in activated T cells through
various mechanisms. The cell cycle inhibitor p27kip1 acts dur-
ing late G1 phase by binding and inhibiting cdk2-cyclin E/A
complexes. Upon stimulation, T cells can progress through the
cell cycle only when p27kip1 is dissociated from the cdk2-cyclin
E/A complexes. This is generally achieved by degradation of
p27kip1, which is preceded by phosphorylation of p27kip1 (61,
63). VIP increased the p27kip1 that coimmunoprecipitated with
cyclin E-cdk2 in comparison to unstimulated and CD3/CD28-
stimulated T cells (Fig. 6A; see Fig. S6A in the supplemental
material), which is consistent with the VIP-mediated decrease
in cyclin E-cdk2 activities. On the other hand, VIP impaired
the binding of p27kip1 to cyclin D2/D3-cdk4 complexes (Fig.
6A; see Fig. S6A in the supplemental material). Furthermore,
VIP treatment prevented the p27kip1 degradation that occurs
upon T-cell activation. VIP-treated T cells showed increased
levels of p27kip1 in the nucleus in comparison with untreated
CD3/CD28-stimulated cells, which showed nuclear exclusion of
p27kip1 (see Fig. S6B in the supplemental material). Increase in
p27kip1 could be a consequence of impaired p27kip1 degradation
and/or of increased p27kip1 synthesis. Our data indicate that VIP
prevented CD3/CD28-induced p27kip1 phosphorylation while in-
creasing total p27kip1 levels (Fig. 6B). Indeed, VIP induced sus-
tained gene expression of p27kip1 (Fig. 6C). Moreover, the induc-
tion of p27kip1 mRNA by VIP was blocked by the transcription
inhibitor actinomycin D (Fig. 6C). The effect of VIP seems to be
selective for p27kip1, since VIP did not affect the levels of other
CDK inhibitors, such as p21cip1 and p16ink4a (see Fig. S7A in the
supplemental material).
The expression of p27kip1 protein is upregulated at the tran-
scriptional level by the winged-helix family of transcription
factors, FOXO1, FOXO3, and FOXO4 (13, 55, 63,). Each of
these Forkhead factors contains conserved phosphorylation
sites for protein kinase B (PKB/Akt), and Akt-mediated phos-
phorylation results in translocation of these factors to the cy-
toplasm and subsequent proteasomal degradation (13, 18, 55).
Consistent with previous reports (46), primary T cells express
relatively high levels of FOXO1 (Fig. 7A) and very low levels
of FOXO3 and FOXO4 (data not shown). VIP inhibited the
phosphorylation and the cytoplasmic translocation of FOXO1
promoted by CD3/CD28 stimulation (Fig. 7A).
Therefore, we next investigated the capacity of VIP to reg-
FIG. 4. VIP requires CTLA4 to induce FoxP3 and to generate Treg.
(A) Purified CD4 CD25 T cells were CD3/CD28 activated in the
absence (none) or presence of VIP, with or without anti-CTLA4 (10
g/ml), anti-TGF- (10 g/ml), or control IgG (10 g/ml). After 96 h,
FoxP3 expression was quantitated by real-time PCR and normalized to
18S rRNA. Unstimulated CD4 CD25 and CD4 CD25 T cells
were used as negative and positive controls, respectively. The error
bars indicate SD. (B) CD4 CD25 T cells from donor A were CD3/
CD28 activated in the absence (CD4control) or presence (CD4VIP) of
VIP, with or without anti-CTLA4, anti-TGF-, or control IgG. After
96 h, the recovered cells (4  104) were cocultured with CFSE-labeled
CD4 cells (2  105; donor A) and mDCs (4  104; donor B). After
96 h, the total number of cycling cells (percent CFSE-positive cells that
had divided  total number of cells) was determined. The shaded
histograms represent examples of each experimental group, and the
solid-line histogram corresponds to CD4 cells stimulated with alloge-
neic mDCs. #, P  0.01. n  3, in duplicate.
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ulate signaling by the PI3K-Akt pathway. T-cell activation
through the CD3/TCR-CD28 pathways resulted in increased
Akt kinase activity as a consequence of its phosphorylation on
Thr308 by PDK-1, which is phosphorylated/activated by PI3K
(Fig. 7B). VIP significantly inhibited all these events (Fig. 7B).
The inhibitory effect of VIP on Akt could be a consequence of
impaired PI3K activity (as the inhibition of PDK-1 phosphor-
ylation suggests) or of increased phosphatase activity on Akt.
To test both possibilities, we investigated the effects of per-
oxovanadate and 740 Y-P, nonselective and selective activators
of PI3K, and of okadaic acid, a phosphatase P2 (PP2) inhibitor.
The three compounds partially reversed VIP effects on Akt
activation, FOXO1 phosphorylation, and p27kip1 levels (Fig.
7C) and the effects of VIP on the inhibition of T-cell prolifer-
ation and cell cycle progression and the induction of suppres-
sive T-cell activities (Fig. 7D), suggesting that inhibition of the
PI3K/Akt pathway plays a major role in the VIP actions on cell
cycle and Treg functions.
Multiple mechanisms are involved in the inhibition of IL-2
production by VIP. Because IL-2 is a hallmark of T-cell acti-
vation and decreased IL-2 production is a mandatory require-
ment to induce hyporesponsive T cells and suppressive func-
tions by VIP (Fig. 2A and 5B), we investigated the mechanisms
related to the VIP-mediated inhibition of IL-2 secretion. By
using a luciferase-linked reporter system in Jurkat T cells, we
found that VIP downregulated CD3/CD28-induced IL-2 tran-
scription and the transactivation mediated by the transcription
factors NF-	B, NFAT, and AP-1 (see Fig. S8 in the supple-
mental material). In agreement, VIP decreased the nuclear
translocation and DNA binding of NF-	B, NFAT, and AP-1
induced by CD3/CD28 signaling in primary T cells (Fig. 8A).
AP-1 and NFAT promoter elements are critical for the tran-
scriptional activity of IL-2, and their defective transactivation
causes T-cell anergy (10, 39). Upon T-cell activation, the
NFAT protein is dephosphorylated and translocates into the
nucleus, and AP-1 is activated by phosphorylation of one of its
components (c-Jun) by two mitogen-activated protein kinase
(MAPK) cascades, finally involving ERK and JNK. VIP im-
paired the translocation of NFATp from the cytoplasm to the
nucleus and decreased the levels of the phosphorylated form of
c-Jun (Fig. 8B). Therefore, we investigated whether the ERK-
MAP kinase pathway was affected by VIP. ERK1 and ERK2
FIG. 5. VIP-induced suppressive T cells are arrested at the early G1 phase of the cell cycle. (A) Effects of VIP on the expression of G1 cyclins
and CDK and CDKi proteins. Human T cells were CD3/CD28 activated without or with VIP (107 M) for different time intervals. The cell lysates
were subjected to Western blot analysis for cyclins, CDKs, p27kip1, phosphorylated pRb (ppRb), or actin. (B) IL-2 partially reverses VIP effects
on cyclins and p27kip1. Human T cells were CD3/CD28 activated without or with VIP (107 M) and IL-2 (50 U/ml) for 72 h. Western blot analysis
was performed on cell lysates for cyclins, p27kip1, and Zap70. (C) VIP inhibits cyclin/CDK activity. Human T cells were CD3/CD28 activated
without or with VIP (107 M) for 36 h. The cell lysates were immunoprecipitated (IP) with Abs against cyclin D2, cyclin D3, cyclin E, cdk2, or
cdk4. Cyclin D2-cdk4, cyclin D3-cdk4, and cyclin E-cdk2 interactions were determined by Western blot (wb) analysis of precipitates with anti-cyclin
D2, anti-cyclin D3, and anti-cdk2, respectively. cdk4-cyclin D2/D3 and cyclin E-cdk2 kinase activities were measured using pRb-GST and histone
H1, respectively, as substrates. n  3. (See Fig. S5 in the supplemental material for quantitative analysis.) unstim, unstimulated.
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are activated through phosphorylation by MEK1 and MEK2,
which are phosphorylated/activated by Raf1 protein kinase. VIP
decreased the levels of phosphorylated ERK1/2 and MEK1 and
inhibited Raf1 kinase activity induced by TCR/CD3-CD28 co-
stimulation (Fig. 8C). Interestingly, VIP did not affect the
phosphorylation/activation of other MAPKs, such as p38 or
JNK (see Fig. S7B in the supplemental material), suggesting a
selective effect of VIP on the phosphorylation of c-Jun by the
Raf1-MEK1-ERK pathway.
The kinase activity of Raf1 is regulated by the Ras family of
small GTP-binding proteins, Ras and Rap1. Ras-Raf1 interac-
tion activates Raf1, and phosphorylation of Rap1 forms Rap1-
GTP, which competes with Ras for binding to Raf1 (9, 50).
Furthermore, Raf1 activity depends on its phosphorylation
status: phosphorylation on Ser43 impairs its kinase activity,
whereas phosphorylation on Ser259 reduces binding to Ras
(17). VIP increased the levels of both phosphorylated forms of
Raf1 (Fig. 8D), suggesting that VIP could directly affect Raf1
kinase activity and reduce its binding to Ras. Interestingly, VIP
also affected CD3/CD28-mediated Ras activation (Fig. 8D),
suggesting that VIP inhibition of Raf1 by phosphorylation
should not be required to inhibit the MEK-ERK1/2 pathway,
because Ras is upstream of Raf1. Moreover, contrary to the
VIP effects found in other cell types (1, 51), VIP impaired the
activation of Rap1-GTP in stimulated T cells (Fig. 8D), indi-
cating that Rap1-GTP competition for Ras is not involved in
the VIP effect on Raf1 activation.
VIP mediates the suppressive effect by elevating cAMP lev-
els. The immunological actions of VIP are exerted through a
family of receptors, consisting of VPAC1 and VPAC2, coupled
to AC and the elevation of intracellular cAMP levels and
subsequent PKA activation (29). Indeed, VIP rapidly and for a
long time increased the cAMP levels and PKA activity in CD3/
CD28-activitated T cells (Fig. 9A). However, VIP did not affect
the intracellular calcium fluxes (see Fig. S7C in the supplemen-
tal material) or the activation of PKC (data not shown) in-
duced by TCR signaling. To determine whether the cAMP/
PKA pathway mediates the regulatory actions described in this
study for VIP, we assayed the effects of H89 (a PKA inhibitor),
forskolin (a cAMP-inducing agent), 8-Br-cAMP (a cell-perme-
able cAMP analogue), and Rp-cAMP (an AC inhibitor). The
VIP effects on cell cycle arrest, CTLA4 expression, T-cell-
suppressive activity, cyclin-CDK activity, p27kip1 phosphoryla-
tion and stability, FOXO1 phosphorylation, ERK1/2 activa-
tion, and phosphorylation of Akt and Raf1 were reversed by
both AC and PKA inhibitors (Fig. 9B to E; see Fig. S9 in the
supplemental material). Forskolin and 8-Br-cAMP mimicked
VIP actions (Fig. 9B to E; see Fig. S9 in the supplemental
material). These findings indicate that the regulatory effects of
VIP on T cells are mainly mediated through increases in in-
tracellular cAMP and PKA activation.
DISCUSSION
In this report, we provide evidence that VIP treatment in the
presence of TCR signaling and CD28 costimulation induces a
regulatory CD4 CD25high T-cell subset from peripheral hu-
man CD4 CD25 responder T cells. Apparently, VIP directly
programs the CD4 CD25 cell toward a regulatory pheno-
type independently of the presence of naturally occurring Treg.
In fact, VIP failed to promote the growth of existing human
Treg in vitro (48) and VIP protected against experimental au-
toimmune encephalomyelitis and arthritis in CD25-depleted
mice by inducing the emergence of new peripheral CD4
FIG. 6. VIP maintains threshold levels of p27kip1. Human T cells were CD3/CD28 activated without or with VIP (107M). (A) VIP increases
the interaction of p27kip1 with cyclin/CDK complexes. Cell lysates obtained after 24 h of culture were immunoprecipitated (IP) with Abs against
cyclin D2, cyclin E, cdk2, or cdk4 and analyzed by Western blotting (wb) for cyclins, CDK, and p27kip1 (see Fig. S6A in the supplemental material
for quantitative data). (B) VIP inhibits p27kip1 phosphorylation in activated T cells. After 48 h of culture, the cell lysates were immunoprecipitated
with anti-p27kip1 Abs and analyzed by Western blotting for p27kip1 (total p27kip1) or phospho-Thr (phosphorylated p27kip1 [P-p27kip1]) and
expressed as densitometric units relative to unstimulated samples. The error bars indicate SD. (C) VIP increases p27kip1 mRNA levels. p27kip1
mRNA expression was determined by Northern blotting and expressed as densitometric units relative to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). When indicated, actinomycin D (ActD) was added during culture (the blot corresponds to 12 h). *, P  0.001 versus CD3/CD28
(n  3).
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CD25 Treg (20, 27, 28). Phenotypically, VIP-converted hu-
man suppressive T cells retain surface CD25 and express high
levels of FoxP3 and CTLA4, but not markers of activation. It
remains unknown whether VIP uniformly affects the entire
CD4 CD25 T-cell repertoire or only a subset that differen-
tiates into FoxP3 CD4 CD25 Treg, which subsequently
suppresses the clonal expansion to the remaining T cells, and
whether these cells are initially committed to differentiate on
Treg. The mechanisms through which VIP stimulates this reg-
ulatory capacity could be defined by two key events that occur
with VIP treatment: induction of cell cycle arrest and increase
on CTLA4 expression.
Evidence now exists that T-cell anergy is clearly related to
generation of Treg (5, 10, 11, 14, 35, 37). The VIP-converted
Treg share a number of biochemical characteristics with anergic
T cells generated following other approaches, including CD28
blockade and CD40L costimulation, or treatments with IL-10
plus TGF-1 or immunosuppressive agents (1, 5, 6, 9, 10, 11,
14, 17, 27, 30, 33, 35, 43, 51). Understanding the molecular
players in the cell cycle regulated during the induction of T-cell
FIG. 7. VIP inhibits FOXO1 phosphorylation and the Akt/PI3K pathway. Human T cells were cultured with medium (unstim) or CD3/CD28
activated in the absence or presence of VIP (107 M). (A) VIP inhibits phosphorylation and cytoplasmic translocation of FOXO1. Total cell
extracts isolated at 4 h of culture (left) or nuclear and cytoplasmic protein extracts isolated at 8 h of culture (right) were analyzed by Western
blotting for FOXO1 or phospho-FOXO1 and expressed as densitometric units relative to total FOXO1, laminin B, or -tubulin. The error bars
indicate SD. (B) VIP inhibits Akt/PKB phosphorylation and kinase activity in stimulated T cells. Cell lysates isolated after 2 h of culture were
analyzed by Western blotting for phospho-Akt and PDK1 and expressed as densitometric units relative to total Akt or PDK1. Akt kinase activity
was determined as described in Materials and Methods and expressed as percentages of the Akt activity of CD3/CD28-activated T cells. (C) The
VIP effect on Akt activity is dependent on PI3K and PP2A activities. CD3/CD28-stimulated human T cells were treated with VIP and/or the PI3K
activators peroxovanadate (PV) (50 M) and 740 Y-P (20 M) or the PP2A inhibitor okadaic acid (OA) (1 M). Western blot analysis was
performed on cell lysates isolated 2 h (for phospho-Akt), 4 h (for phospho-FOXO1), or 48 h (for p27kip1) of culture. The results are expressed as
densitometric units relative to total Akt or -tubulin. (D) Involvement of inhibition of PI3K-Akt signaling in the VIP effect on the T-cell cycle and
regulatory functions. CD3/CD28-activated human T cells were treated with VIP and/or PV, OA, or 740 Y-P. The percentage of cells in S phase
and proliferation were determined after 72 h. After 96 h in culture, T cells were recovered, and their suppressive potential was determined in
cocultures with syngeneic responder T cells (at a suppressor/responder ratio of 1:2) and allogeneic mDCs, as described in the legend to Fig. 3A,
and expressed as a percentage of inhibition of proliferation. n  3 or 4. *, P  0.01 versus CD3/CD28; #, P  0.01 versus VIP-treated samples.
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anergy may provide a powerful tool in quantifying the degree
of tolerance induction in individual patients who receive T cells
tolerized by different strategies. Our data indicate that VIP-
treated T cells are capable of entering the G1 phase but do not
progress through the G1 restriction point to the late G1 and S
phases. Blockade of cell cycle progression by VIP could be
exerted at multiple levels (see Fig. S10 in the supplemental
material). VIP impairs the activation of the cdk4-cyclin D3 and
cdk2-cyclin E complexes, which are needed to phosphorylate
pRb in two different moments of the G1 phase, and thereby
deactivates the E2F transcription factor and inhibits the ex-
pression of S-phase genes. The inhibition of the G1 CDK-
cyclin holoenzymes could be in part a consequence of VIP-
induced reduction of cyclin D3 and cyclin E levels, which are
synthesized at late G1 phase and the G1 restriction point,
respectively. Moreover, VIP keeps the levels of the cell cycle
inhibitor p27kip1 elevated on activated T cells. Independently
of the amounts of cyclins synthesized during T-cell activation,
p27kip1 must be dissociated from the cdk2-cyclin E complexes
to permit G1/S progression (63). Whereas cdk2-cyclin E activ-
ity is highly sensitive to p27kip1, cdk4-cyclin D complexes
are catalytically active even in the presence of high levels of
p27kip1. In fact, it has been proposed that cdk4-cyclin D com-
plexes function to sequester p27kip1 away from cdk2-cyclin E
(63). Interestingly, VIP favors the interaction of p27kip1 with
cdk2-cyclin E complexes, but not with cdk4-cyclin D2 com-
plexes, through a mechanism that is still unknown. However,
VIP treatment decreases the activation of the cdk4-cyclin D2
complexes without affecting their expression. Because cdk4
activation depends on its phosphorylation by Akt, VIP-induced
Akt inhibition could partially explain the suppressive activity of
VIP on cdk4-cyclin D2 activation. It is plausible that the in-
duction of p27kip1 by VIP plays a central role in the effect of
VIP on cell cycle arrest, an effect that seems to occur at two
levels. VIP inhibits the phosphorylation and subsequent deg-
radation of p27kip1 and also stimulates gene expression of
p27kip1. Since p27kip1 is phosphorylated by PKB/Akt and cdk2,
among others, VIP inhibition of both kinases could prevent
p27kip1 phosphorylation/degradation. Furthermore, as previ-
ously described (13, 18, 46, 55), inhibition of Akt-mediated
phosphorylation of the transcription factor FOXO1 could in-
crease the transcription of p27kip1, because FOXO1 binds to
the p27kip1 promoter only in its dephosphorylated form. More-
over, a recent work using FOXO1-deficient mice has demon-
strated the critical role of this factor in T-cell activation and
tolerance (44). Regulation of p27kip1 at both the transcrip-
FIG. 8. Mechanisms of inhibition of IL-2 expression by VIP. (A) Human T cells were cultured with medium (unstim) or CD3/CD28 activated
without or with VIP (107 M). After 4 h, nuclear proteins were isolated and assayed for DNA binding to NF-	B, AP-1, or NFAT consensus sites
by EMSA and expressed as densitometric units relative to the binding of the constitutive nuclear factor NF-Y. The error bars indicate SD. (B) After
3 h, whole-cell extracts were analyzed by Western blotting for c-Jun and phospho-c-Jun expression. NFATp levels were determined in both nuclear
and cytoplasmic extracts and expressed as densitometric units relative to laminin B or -tubulin. (C) After 1 h of culture, cell lysates were prepared,
and activation of ERK1/2 and MEK1 was determined by Western blotting with phosphospecific Abs and expressed as densitometric units
normalized for total ERK1/2 or MEK1. The kinase activity of Raf1 was determined by assaying the phosphotransferase activity toward GST-
MEK1. (D) Activation of Rap1 and Ras was determined as described in Materials and Methods. The inactive forms of Raf1 were measured in
cell lysates by Western blotting for phospho-Ser43-Raf1 and phospho-Ser259-Raf1. n  3 or 4. *, P  0.01 versus CD3/CD28.
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tional and posttranslational levels could explain why the inhib-
itory signal of VIP on cell cycle dynamics is maintained long
term and does not require treatment for extended periods. As
in the cases of other antiproliferative treatments (3), inhibition
of the PI3K-Akt pathway appears to be critical for VIP regu-
lation of p27kip1. Our data support the involvement of both
PP2-mediated Akt dephosphorylation and inhibition of PI3K
activity in the VIP effects. Whether VIP affects any factor
FIG. 9. VIP mediates the suppressive effect by elevating cAMP levels. (A) VIP increases cAMP levels and stimulates PKA activity in human
activated T cells. Human T cells were CD3/CD28 stimulated with or without VIP (107 M). Intracellular cAMP levels were determined at different
times (top). PKA activity was assayed by radioimmunoassay in cell lysates obtained 1 h after stimulation (bottom). The error bars indicate SD. (B
to E) Human T cells were CD3/CD28 stimulated in the absence () or presence of forskolin (106 M), 8-Br-cAMP (0.1 mM), or VIP (107 M)
with or without H89 (50 ng/ml) or Rp-cAMP (0.1 mM). (B) Cell cycle analysis was performed after 72 h. (C) Expression of the soluble and
membrane forms of CTLA4 was determined at 96 h. (D) The suppressive activity on effector T cells was determined as described in the legend
to Fig. 3A at an effector/suppressor cell ratio of 2:1. (E) The expression and phosphorylation statuses of cyclins, CDK, p27kip1, FOXO1, Akt, Raf1,
and ERK1/2 and the activation of cyclin-CDK complexes and Ras were quantified as detailed in the legends to Fig. 5 to 8. The specificity of H89
and Rp-cAMP in our study was confirmed by their blocking effects on the actions of forskolin and Br-cAMP. Representative blots are shown in
Fig. S9 in the supplemental material. n  3 or 4. *, P  0.001 versus CD3/CD28; #, P  0.001 versus VIP-treated samples.
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localized upstream of PI3K is unknown; however, VIP does
not regulate initial TCR signaling through Zap70 (data not
shown), p59fyn or p56lck tyrosine kinase, or the  chain associ-
ated with TCR (see Fig. S7D to F in the supplemental mate-
rial). The capacity of PP2A to deactivate G1 CDKs, including
cdk2 and cdk4 (65), could also explain why VIP slightly de-
creases cdk4-cyclin D2 activity while keeping cyclin D2 and
cdk4 levels unaffected. The activation of the cAMP/PKA path-
way seems to play a major role in all these VIP actions. Indeed,
the effects of other cAMP/PKA-inducing agents in T-cell cycle
arrest and p27kip1 upregulation are well known (10, 30, 31, 42,
50, 59).
A decrease in IL-2 production accompanies the effect of VIP
on cell cycle arrest. This seems to be critical to reinforce T-cell
hyporesponsiveness, since exogenous IL-2 partially reverses
this state. As with CD3/CD28 signaling, VIP is able to block
the activation of the PI3K-Akt and Ras-Raf1-ERK1/2 cascades
induced by IL-2 (see Fig. S7G in the supplemental material).
However, IL-2 signaling seems to partially bypass the suppres-
sive action of VIP through the activation of the STAT5 path-
way, which is not affected by VIP (see Fig. S7G in the supple-
mental material). Activation of STAT5 is critically involved in
the mitogenic effects of IL-2, because it directly activates cru-
cial genes, including cyclins D2/D3, cdk4/6, and c-Myc (41).
However, although the PI3K and Ras-MAPK pathways are
crucial for T-cell activation through the TCR (64), its absolute
requirement in IL-2-mediated signaling has been more difficult
to demonstrate, since it is mainly cooperative with the STAT5
signal (24, 40). Although VIP does not fully block IL-2 signal-
ing, our study clearly demonstrates that VIP deactivates three
of the transcription factors, NFAT, NF-	B, and AP-1, critically
involved in IL-2 transcription and T-cell activation. It was
reported that VIP inhibits NFAT dephosphorylation and nu-
clear translocation without affecting calcineurin activity (15).
Therefore, PKA-mediated phosphorylation of NFAT emerges
as a plausible mechanism for the inhibitory effect of VIP on
NFAT (32). Regarding NF-	B, various studies clearly demon-
strated that VIP regulates NF-	B activation by inhibiting the
phosphorylation/degradation of the NF-	B inhibitor I	B (15,
16, 29). Alternatively, because PDK1 integrates TCR-CD28
signaling and NF-	B activation (45), VIP could impair NF-	B-
dependent gene activation by inhibiting PDK1. Finally, AP-1
inhibition by VIP is more complex and involves downregula-
tion of the Ras-Raf1-MEK1-ERK cascade. Interestingly, VIP
does not affect the activation of JNK and p38 MAPK, which
could be more dependent on kinases other than Ras-Raf1. Our
results provide evidence that VIP treatment directly inhibits
Ras kinase activity and impairs the activation of Raf1 and its
binding to Ras. VIP effects on the Ras-Raf1-MEK1-ERK sig-
naling cascade are cell type specific, since, contrary to our
findings in T cells, VIP stimulates this pathway in other cells (1,
51). Interestingly, cAMP/PKA signaling is involved in both
VIP inhibitory and stimulatory actions. Beside the effects on
IL-2 production, VIP inhibition of Ras-Raf1 could affect cell
cycle regulation, since interaction of Raf1 with Cdc25 phos-
phatases activates CDKs during the G1/S transition (22).
On the other hand, our study demonstrates that CTLA4
plays a major role in the generation and regulatory activity of
the VIP-induced Treg. Interestingly, although VIP also stimu-
lates the production of IL-10, a cytokine frequently linked to
the regulatory activity of induced Treg (38, 54), IL-10 seems to
play a minor role, if any, in the suppressive activity of the
VIP-tolerized T cells. Moreover, TGF-, although critical in
the generation of other Treg subtypes (10, 14, 19, 53, 66), does
not participate in the induction of Treg by VIP. CTLA4 has
striking inhibitory effects on T-cell activation and is essential
for maintaining immune tolerance (12). Besides its essential role
in the suppressive activity of Treg (21), CTLA4 costimulation
appears to be needed for generating adaptive CD4 CD25
suppressor cells (67). Similarly, VIP requires CTLA4 to induce
CD4 CD25 FoxP3 cells to become CD4 CD25 FoxP3
suppressor cells. VIP not only increases the expression of CTLA4
in T cells, but also accelerates its appearance and maintains ele-
vated levels long term. The presence of CTLA4 early after T-cell
activation critically contributes, in an autocrine/paracrine manner,
to the tolerizing activity of VIP. However, CTLA4 seems to play
a minor role in the cell cycle arrest and hyporesponsive state of
the VIP-tolerized T cells, suggesting that this is an effect directly
exerted on molecular players in cell cycle progression. In addition,
VIP does not induce other molecules involved in negative signal-
ing in T cells, such as BTLA4 and PD-1. The fact that VIP induces
both soluble and membrane-bound forms of CTLA4 explains why
the suppressive activity of VIP-induced Treg is entirely CTLA4
dependent but only partially cell-to-cell contact dependent.
Again, signaling through cAMP/PKA appears to be critical for
the VIP effects on CTLA4 increase and subsequently on FoxP3
expression. In agreement with this, other cAMP-inducing agents
were previously found to increase FoxP3 and CTLA4 expression
in CD4 cells (5, 60). Therefore, it is likely that the sustained
elevation of cAMP plays a unique role in the generation and
regulatory activity of the VIP-induced Treg. Consistent with these
findings, elevated intracellular cAMP was identified as a hallmark
of Treg (23), and Treg partially exert the suppressive activity by
transferring cAMP to effector T cells through gap junctions (8).
Therefore, VIP-generated Treg could partially exert their function
through this cell-to-cell contact-dependent mechanism.
In summary, we are proposing an alternative strategy for
developing Treg immunotherapy by generating human Treg ex
vivo from conventional CD4 CD25 FoxP3 T cells, a
method that would be more convenient than expanding natural
Treg and more feasible for generating antigen/organ-specific
Treg. Understanding precisely how VIP controls immunoregu-
latory mechanisms will help to further its use in the clinic. For
now, we must wait to see whether the inclusion of VIP-gener-
ated antigen-specific Treg ex vivo in future therapeutic regi-
mens will be of value. However, some evidence indicates that
the findings reported here are of physiological and clinical
relevance. For example, the treatment with aerosolized VIP of
patients with sarcoidosis, a systemic autoimmune granulomatous
disease, significantly increased the number of functional Treg in
bronchoalveolar fluid (49). Moreover, patients suffering from
rheumatoid arthritis, multiple sclerosis, and systemic lupus ery-
thematosis have less circulating VIP or VIP receptor than healthy
subjects (2), suggesting a correlation between susceptibility to
autoimmune disorders and defective VIP signaling.
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